Astera Labs, Inc. $ALAB Shares Sold by SteelPeak Wealth LLC

SteelPeak Wealth LLC lowered its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 28.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,283 shares of the company’s stock after selling 1,739 shares during the quarter. SteelPeak Wealth LLC’s holdings in Astera Labs were worth $469,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. grew its holdings in shares of Astera Labs by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 13,827,506 shares of the company’s stock worth $2,300,344,000 after purchasing an additional 84,365 shares during the period. State Street Corp lifted its position in Astera Labs by 32.5% in the fourth quarter. State Street Corp now owns 3,099,809 shares of the company’s stock valued at $515,684,000 after buying an additional 760,358 shares during the last quarter. Geode Capital Management LLC lifted its position in Astera Labs by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 2,429,078 shares of the company’s stock valued at $403,598,000 after buying an additional 104,935 shares during the last quarter. Fred Alger Management LLC boosted its stake in Astera Labs by 25.5% during the fourth quarter. Fred Alger Management LLC now owns 1,934,688 shares of the company’s stock worth $321,855,000 after buying an additional 393,250 shares during the period. Finally, Morgan Stanley increased its position in shares of Astera Labs by 33.0% during the fourth quarter. Morgan Stanley now owns 1,934,467 shares of the company’s stock valued at $321,818,000 after acquiring an additional 480,009 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Activity

In other Astera Labs news, Director Stefan A. Dyckerhoff sold 3,505 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $450.00, for a total transaction of $1,577,250.00. Following the sale, the director directly owned 57,466 shares in the company, valued at $25,859,700. This represents a 5.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Sanjay Gajendra sold 400,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $290.30, for a total transaction of $116,120,000.00. Following the completion of the transaction, the chief operating officer directly owned 5,064,213 shares of the company’s stock, valued at $1,470,141,033.90. This represents a 7.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,700,432 shares of company stock worth $449,062,723 over the last 90 days. Company insiders own 10.40% of the company’s stock.

Wall Street Analysts Forecast Growth

ALAB has been the topic of a number of research analyst reports. Rothschild & Co Redburn assumed coverage on shares of Astera Labs in a research note on Friday, May 1st. They issued a “neutral” rating and a $153.00 price target on the stock. Susquehanna increased their price objective on shares of Astera Labs from $155.00 to $230.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. Citigroup downgraded shares of Astera Labs from a “buy” rating to a “market perform” rating in a report on Tuesday, May 26th. Jefferies Financial Group reissued a “buy” rating and issued a $270.00 target price on shares of Astera Labs in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada upped their price target on Astera Labs from $250.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. Twelve analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $275.75.

Astera Labs Price Performance

Shares of NASDAQ:ALAB opened at $303.62 on Friday. The firm has a market capitalization of $52.04 billion, a PE ratio of 205.15, a price-to-earnings-growth ratio of 3.42 and a beta of 3.66. The firm’s 50-day moving average is $349.32 and its two-hundred day moving average is $220.59. Astera Labs, Inc. has a 1 year low of $96.79 and a 1 year high of $499.48.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.07. Astera Labs had a net margin of 26.72% and a return on equity of 18.49%. The business had revenue of $308.36 million for the quarter, compared to analysts’ expectations of $292.19 million. During the same quarter in the prior year, the company earned $0.33 earnings per share. The business’s quarterly revenue was up 93.5% on a year-over-year basis. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. Analysts expect that Astera Labs, Inc. will post 1.88 EPS for the current fiscal year.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.